13F Holdings
中文EN

INCR Intercure Ltd. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1857030 · Reporting currency ILS · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-32.8%
TTM net income YoY-9.4%
TTM EPS YoY-8.8%
Revenue 3-yr CAGR2.8%
Net income 3-yr CAGR—

Margins

Gross margin12.7%
Operating margin-28.1%
Net margin-28.4%
FCF margin-29.9%
EBITDA margin-21.7%

Returns

ROE-15.9%
ROA-8.8%
ROIC (approx.)-10.3%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets47.9%
Debt / equity0.46x
Current ratio1.73x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.1%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: ILS FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue238.84M355.55M388.68M219.68M65.03M
Cost of revenue203.25M247.21M229.73M123.69M34.65M
Gross profit30.23M105.09M155.08M91.13M31.98M
R&D expense414,000388,000632,0001.24M1.58M
SG&A expense53.67M42.61M36.08M27.21M8.59M
Operating income-67.21M-41.57M50.63M28.18M-38.40M
Pretax income-87.32M-61.28M43.84M18.73M-38.31M
Income tax-14.53M2.25M93,00011.44M-2.27M
Net income-67.80M-61.96M44.82M4.69M-37.23M
EBITDA-51.84M-28.40M62.33M35.58M-35.15M
EPS (basic)-1.48-1.360.990.12-1.42
EPS (diluted)-1.48-1.360.990.11-1.42
Balance sheet
Cash & equivalents78.32M101.14M232.59M196.22M37.89M
Short-term investments333,000187,000157,000330,000—
Receivables51.85M60.41M36.92M17.41M12.47M
Inventory120.31M105.47M140.13M62.31M19.05M
Current assets391.80M418.80M527.49M336.16M76.65M
PP&E, netmay include right-of-use assets (IFRS)105.24M97.47M103.13M86.51M53.47M
Goodwill224.59M221.08M284.18M268.29M190.10M
Total assets762.57M786.61M958.01M696.54M326.27M
Current liabilities226.75M225.87M312.72M193.59M29.88M
Short-term debt69.44M88.19M126.94M70.56M357,000
Long-term debt113.98M82.20M99.68M11.88M388,000
Total debt183.41M170.40M226.62M82.44M745,000
Total liabilities364.90M329.55M436.53M227.13M34.16M
Shareholders' equity396.97M455.11M501.31M448.03M274.51M
Net debt105.10M69.26M-5.97M-113.78M-37.14M
Cash flow statement
Operating cash flow-66.93M-53.63M51.27M30.14M7.90M
Capital expenditure4.38M2.62M19.74M14.03M20.84M
Free cash flow-71.30M-56.25M31.52M16.11M-12.95M
Investing cash flow17.69M4.77M-142.50M-65.21M-22.76M
Financing cash flow26.45M-82.89M120.45M197.94M25.20M
Depreciation & amortization15.37M13.17M11.70M7.39M3.25M
Stock-based compensation2.28M2.59M8.91M6.45M10.01M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, ILS, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.